|
๐
|
Circulating microRNAs as stable blood-based markers for cancer detection
20 auth.
P. S. Mitchell,
R. K. Parkin,
E. Kroh,
B. Fritz,
S. Wyman,
E. PogosovaโAgadjanyan,
Amelia C. Peterson,
J. Noteboom,
K. O'Briant,
A. Allen,
...
D. Lin,
N. Urban,
C. Drescher,
B. Knudsen,
Derek L. Stirewalt,
R. Gentleman,
R. Vessella,
P. Nelson,
Daniel B. Martin,
M. Tewari
|
12 |
2008 |
12
๐
|
|
๐ฌ
|
Elevation of cytokine levels in cachectic patients with prostate carcinoma
J. Pfitzenmaier,
R. Vessella,
C. Higano,
J. Noteboom,
D. Wallace,
E. Corey
|
7 |
2003 |
7
๐ฌ
|
|
๐ฌ
|
Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen.
R. Vessella,
J. Noteboom,
P. Lange
|
6 |
1992 |
6
๐ฌ
|
|
๐
|
A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.
12 auth.
L. Sokoll,
W. Ellis,
P. Lange,
J. Noteboom,
D. Elliott,
I. Deras,
...
A. Blase,
S. Koo,
M. Sarno,
H. Rittenhouse,
J. Groskopf,
R. Vessella
|
6 |
2008 |
6
๐
|
|
๐ฌ
|
Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
WILLIAM J. Ellis,
Robert L. Vessella,
J. Noteboom,
Paul H. Lange,
R. Wolfert,
Harry G. Rittenhouse
|
5 |
1997 |
5
๐ฌ
|
|
๐ฌ
|
The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay.
T. Takayama,
R. Vessella,
M. Brawer,
J. Noteboom,
P. Lange
|
5 |
1993 |
5
๐ฌ
|
|
๐ฌ
|
Urinary prostate specific antigen levels after radical prostatectomy.
Thomas K. ฮคakayama,
R. Vessella,
M. Brawer,
L. True,
J. Noteboom,
P. Lange
|
5 |
1994 |
5
๐ฌ
|
|
๐ฌ
|
Serum percent free prostate-specific antigen in metastatic prostate cancer.
D. Lin,
J. Noteboom,
B. Blumenstein,
W. Ellis,
P. Lange,
R. Vessella
|
4 |
1998 |
4
๐ฌ
|
|
๐
|
Bayer immuno 1โข PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum
18 auth.
Deborah L. Morris,
P. Dillon,
D. L. Very,
Phillip Ng,
Linda A. Kish,
Joan L. Goldblatt,
D. Bruzek,
D. Chan,
M. Ahmed,
Deborah Witek,
...
H. Fritsche,
C.A. Smith,
D. Schwartz,
M. Schwartz,
J. Noteboom,
R. Vessella,
K. Yeung,
W. Allard
|
3 |
1998 |
3
๐
|
|
๐ฌ
|
The percentage of free prostateโspecific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy
S. Melchior,
J. Noteboom,
R. Gillitzer,
P. Lange,
B. Blumenstein,
R. Vessella
|
3 |
2001 |
3
๐ฌ
|
|
๐ฌ
|
Evaluationof the Abbott lMx#{174} Automated Immunoassayof Prostate-SpecificAntigen
R. Vessella,
J. Noteboom,
P. Lange
|
3 |
1992 |
3
๐ฌ
|
|
๐
|
Corrigendum to โA multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracyโ [Clinica Chimica Acta 389 (2008)L-6]
12 auth.
L. Sokoll,
W. Ellis,
P. Lange,
J. Noteboom,
Debra J. Elliot,
I. Deras,
...
A. Blase,
S. Koo,
M. Sarno,
H. Rittenhouse,
J. Groskopf,
R. Vessella
|
2 |
2009 |
2
๐
|
|
๐
|
1780TiP A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE)
13 auth.
C. Stockem,
B. V. van Rhijn,
T. Boellaard,
M. V. van Montfoort,
S. Balduzzi,
J. Boormans,
M. Franckena,
R. Meijer,
J. Noteboom,
D. Robbrecht,
...
B. Suelmann,
E. Schaake,
M. S. van der Heijden
|
0 |
2022 |
0
๐
|
